Triglyceride–glucose index as a marker of adverse cardiovascular prognosis in patients with coronary heart disease and hypertension
Authors' conclusion
The elevated TyG index was a potential marker of adverse prognosis in patients with CHD and hypertension.
Study context
- Population
- Hospitalized patients with coronary heart disease (CHD) and hypertension, January 2021 to December 2021
- Participants
- 1,467 patients
- Exposure
- Triglyceride-glucose (TyG) index tertiles
- Outcome
- Composite of:
- First occurrence of all-cause mortality
- Total nonfatal CVD events
- Follow-up
- one-year follow up
Main finding
As reported in the abstract
Primary composite endpoint · one-year follow-up
Estimate (95% CI)P value
T2vs T1
fully adjusted HR 1.43(0.90–2.26)
T3vs T1
fully adjusted HR 1.73(1.06–2.82)
P = 0.018for trendPer SD increase in TyG indexrisk increased by 28%
adjusted HR 1.28(1.04–1.59)
- Primary endpoint events (all patients)
- 154 (10.5%)
Observational data: associations, not effects.
Secondary outcomes
Atherosclerotic CVD (ASCVD) events (non-fatal stroke/TIA and recurrent CHD events) · one-year follow-up
- ASCVD events (all patients)
- 129 (8.8%)
- Similar results were observed in ASCVD events
Original publication
Triglyceride–glucose index as a marker of adverse cardiovascular prognosis in patients with coronary heart disease and hypertension. Cardiovasc Diabetol. Published 9 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →